VistaGen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

VistaGen Therapeutics (NASDAQ:VTGN) released its quarterly earnings results on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06, FiscalAI reports. The firm had revenue of $1.48 million for the quarter, compared to analyst estimates of $0.50 million. VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.

VistaGen Therapeutics Stock Performance

VTGN traded up $0.00 during trading on Friday, reaching $0.27. The company’s stock had a trading volume of 799,470 shares, compared to its average volume of 2,197,639. VistaGen Therapeutics has a 52-week low of $0.20 and a 52-week high of $5.14. The company’s fifty day moving average price is $0.38 and its 200-day moving average price is $0.52. The company has a market capitalization of $11.98 million, a price-to-earnings ratio of -0.15 and a beta of 0.41.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $0.95.

Institutional Trading of VistaGen Therapeutics

Hedge funds have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in VistaGen Therapeutics during the first quarter worth $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in VistaGen Therapeutics in the third quarter valued at $39,000. Boothbay Fund Management LLC boosted its position in shares of VistaGen Therapeutics by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after purchasing an additional 19,166 shares in the last quarter. Bank of America Corp DE grew its stake in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after purchasing an additional 19,331 shares during the period. Finally, Millennium Management LLC purchased a new position in shares of VistaGen Therapeutics in the 3rd quarter valued at about $73,000. 78.39% of the stock is owned by institutional investors and hedge funds.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.